GSK will acquire Nuvalent for $10.6B, adding FDA-reviewed ROS1 and ALK inhibitors. The deal strengthens GSK’s lung cancer pipeline with potential 2026 launches and expands its precision oncology strategy.
Written By: Umesh Hanumante,
M.Pharm (Reg. Affairs)
Reviewed By: Pharmacally Editorial Team
GSK will acquire Nuvalent for $10.6 billion in cash, adding three targeted lung cancer programs led by two late-stage non-small cell lung cancer (NSCLC) therapies currently under U.S. FDA review. The deal brings zidesamtinib (NVL-520), a selective ROS1 inhibitor, and neladalkib (NVL-655), a selective ALK inhibitor, both of which have received FDA Breakthrough Therapy and Orphan Drug designations.
The FDA is expected to issue decisions on zidesamtinib by September 18, 2026, and neladalkib by November 27, 2026. If approved, both therapies could launch this year and provide new treatment options for patients with ROS1- and ALK-positive NSCLC.
The acquisition also includes NVL-330, a Phase 1 HER2 inhibitor for HER2-altered NSCLC, and several preclinical oncology programs.
Building a Precision Lung Cancer Franchise
The transaction accelerates GSK’s expansion into targeted lung cancer, a key growth area within oncology. ROS1- and ALK-driven NSCLC are distinct molecular subtypes that often affect younger patients and remain vulnerable to treatment resistance and disease progression in the central nervous system.
Nuvalent has focused on developing highly selective kinase inhibitors with broad activity against resistance mutations and strong brain penetration. This approach aims to improve disease control while reducing off-target toxicities associated with earlier-generation therapies.
Clinical Profile of Lead Assets
Pivotal data presented at the IASLC World Conference on Lung Cancer and the 2026 ASCO Annual Meeting highlighted durable responses, broad mutation coverage, favorable tolerability, and meaningful intracranial activity for both zidesamtinib and neladalkib.
According to GSK, the compounds’ high target selectivity may support longer treatment duration and address limitations of currently available ROS1 and ALK inhibitors. Both agents have also gained substantial clinical experience through ongoing development programs and patient access initiatives.
Strategic and Financial Impact
GSK CEO Luke Miels said the acquisition aligns with the company’s strategy of acquiring therapies against clinically validated targets that address remaining efficacy and tolerability gaps. He also highlighted the opportunity to build a broader lung cancer franchise alongside Ris-Rez, GSK’s Phase 3 B7-H3 antibody-drug conjugate.
Nuvalent CEO James Porter said the company’s structure-based drug design platform and close collaboration with leading physician-scientists helped accelerate development of its oncology pipeline.
Under the agreement, GSK will acquire all outstanding Nuvalent shares for $124 per share in cash, representing a 40% premium to the company’s closing share price. After accounting for cash on hand, the net investment is expected to be approximately $9.4 billion.
GSK expects the acquisition to contribute to revenue growth from 2027, strengthen operating profit through the dolutegravir loss-of-exclusivity period, and become accretive to core earnings per share in 2029. Subject to regulatory approvals and closing conditions, the transaction is expected to close in the third quarter of 2026.
Reference
About the Writer
Umesh Hanumante (M.Pharm) (LinkedIn) is a pharmacy professional and healthcare writer with a background in Regulatory Affairs, pharmaceutical innovation, and clinical research. He has around two years of industry experience as an Executive PMT at Troikaa Pharmaceuticals Ltd and qualified GPAT 2024. His areas of interest include regulatory compliance, dossier preparation, clinical trials, emerging therapies, and advancements in the global pharmaceutical and healthcare sector.